Volume 10, Issue 6, Pages (June 2009)

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Fever of unknown origin and cancer: a population-based study

Volume 14, Issue 12, Pages (November 2013)

Volume 12, Issue 3, Pages (March 2011)

Volume 14, Issue 4, Pages (April 2013)

Volume 12, Issue 9, Pages (September 2011)

Su K. Metcalfe, MD, MPH, Michael T

Volume 389, Issue 10072, Pages (March 2017)

Volume 357, Issue 9273, Pages (June 2001)

Volume 16, Issue 2, Pages (February 2015)

Volume 17, Issue 5, Pages (May 2016)

BMI and risk of dementia in two million people over two decades: a retrospective cohort study Dr Nawab Qizilbash, MRCP, John Gregson, PhD, Michelle E.

Volume 12, Issue 11, Pages (October 2011)

Volume 18, Issue 7, Pages (July 2017)

The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis K.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Volume 14, Issue 9, Pages (August 2013)

Volume 14, Issue 4, Pages (April 2013)

Volume 13, Issue 12, Pages (December 2012)

Intraoperative radiotherapy for early breast cancer

Quantitative Fluorescence in Situ Hybridization and its Ability to Predict Bladder Cancer Recurrence and Progression to Muscle-Invasive Bladder Cancer

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study Thomas.

Volume 13, Issue 3, Pages (March 2012)

Volume 15, Issue 8, Pages (July 2014)

Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study Matthew Waxman, MD,

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy Michele.

Volume 15, Issue 4, Pages (April 2014)

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Volume 18, Issue 7, Pages (July 2017)

Volume 379, Issue 9835, Pages (June 2012)

Volume 18, Issue 3, Pages (March 2017)

Volume 15, Issue 1, Pages (January 2014)

Volume 356, Issue 9241, Pages (November 2000)

Psychological response and survival in breast cancer

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Volume 13, Issue 12, Pages (December 2012)

Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327) Primo N. Lara,

Volume 6, Issue 6, Pages (June 2005)

Volume 393, Issue 10171, Pages (February 2019)

Volume 14, Issue 11, Pages (October 2013)

Volume 385, Issue 9962, Pages (January 2015)

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

Volume 2, Issue 6, Pages e243-e251 (June 2015)

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Volume 20, Issue 1, Pages (January 2019)

Volume 9, Issue 4, Pages (April 2008)

Volume 5, Issue 4, Pages (April 2018)

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Volume 373, Issue 9658, Pages (January 2009)

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

ACST: which subgroups will benefit most from carotid endarterectomy?

Volume 371, Issue 9618, Pages (March 2008)

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Volume 14, Issue 7, Pages (June 2013)

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial Barbara J.

A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Volume 20, Issue 8, Pages (August 2019)

Presentation transcript:

Volume 10, Issue 6, Pages 581-588 (June 2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study Dr Bella Kaufman, MD, Prof Maureen Trudeau, MD, Prof Ahmad Awada, MD, Kimberly Blackwell, MD, Thomas Bachelot, MD, Vanessa Salazar, BS, Michelle DeSilvio, PhD, Ronald Westlund, MS, Tal Zaks, MD, Neil Spector, MD, Stephen Johnston, MD The Lancet Oncology Volume 10, Issue 6, Pages 581-588 (June 2009) DOI: 10.1016/S1470-2045(09)70087-7 Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 1 Study populations and design *HER2-overexpressing (HER2+) patients had HER2 immunohistochemistry (IHC) 3+ or fluorescence in-situ hybridisation (FISH) amplified tumours. 15 patients from cohort A had tumours that were HER2 2+ without FISH amplification. The Lancet Oncology 2009 10, 581-588DOI: (10.1016/S1470-2045(09)70087-7) Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 2 Clinically evaluable skin disease Before treatment with lapatinib (A) and response after 84 days (B) of lapatinib therapy. The Lancet Oncology 2009 10, 581-588DOI: (10.1016/S1470-2045(09)70087-7) Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 3 Kaplan-Meier estimates of investigator-assessed progression-free survival in the HER2+ positive population The Lancet Oncology 2009 10, 581-588DOI: (10.1016/S1470-2045(09)70087-7) Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 4 Kaplan-Meier estimates of overall survival since first dose of treatment in the HER2+ population The Lancet Oncology 2009 10, 581-588DOI: (10.1016/S1470-2045(09)70087-7) Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 5 Mean change from baseline in 33 patients with brief pain inventory (BPI)–short form pain scores Error bars are 95% CI. The Lancet Oncology 2009 10, 581-588DOI: (10.1016/S1470-2045(09)70087-7) Copyright © 2009 Elsevier Ltd Terms and Conditions